Lynavoy is used to treat cholestatic pruritus, an extreme itch that affects almost 90% of patients with primary biliary cholangitis.
The FDA approved linerixibat (Lynavoy) as the first drug indicated for cholestatic pruritus stemming from primary biliary ...
Everyday Health on MSN
Why primary biliary cholangitis causes itching — and how to find relief
Learn why primary biliary cholangitis (PBC) causes intense itching, and explore treatment options, management tips, and skin-care strategies for relief.
Alfasigma’s buzzer-beater bet on GSK’s rare liver disease prospect has paid off. | Lynavoy is now the first FDA-approved product that can treat cholestatic pruritus in patients with primary biliary ...
March 19 (Reuters) - The U.S. Food and Drug Administration approved GSK's drug for severe relentless itching caused ...
GSK (GSK) stock is in focus as the company wins FDA nod for Lynavoy, the first U.S. treatment for cholestatic pruritus in ...
March 9 (Reuters) - GSK said on Monday it will receive up to $690 million from Italian pharmaceutical company Alfasigma for ...
London: The U.S. Food and Drug Administration approved GSK's drug for severe relentless itching caused by a type of liver ...
GlobalData on MSN
Mirum concludes Phase III EXPAND trial enrolment for Livmarli
The double-blind, randomised, placebo-controlled trial will assess the efficacy and safety of Livmarli in both children and ...
The British pharma giant will hand off its experimental itch treatment to Italian company Alfasigma as it focuses on broader ...
Pharmaceutical Technology on MSN
GSK sells liver disease drug candidate to Alfasigma for $690m
GSK’s linerixibat is currently under regulatory review in the US, Europe, and China, amongst other regions.
For the best experience, please enable JavaScript in your browser settings. UK: A tormented toddler's rare liver disease causes him to itch so much he deliberately ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results